ArriVent Q2 net loss $39.3M; cash $298.7M funds into 2026; firmonertinib data at WCLC

ArriVent BioPharma, Inc.

2024-Q2 EPS reported -$1.34

Net loss for six months ended June 30, 2024 was $39.3M, compared to $33.7M in prior year period.
Cash and cash equivalents $298.7M as of June 30, 2024; expected to fund operations into 2026.
R&D expenses $38.8M (up from $30.6M) due to increased headcount and firmonertinib clinical costs.
Interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC to be presented at WCLC presidential symposium on Sept 9, 2024.
Entered ADC collaboration with Alphamab to discover and develop novel ADCs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.